Skip to main content
Clinical Trials/NCT04305067
NCT04305067
Completed
Not Applicable

PRECISE: PancREatic Cancer and Individualised Supervised Exercise: a Feasibility Study

Queen's University, Belfast1 site in 1 country8 target enrollmentAugust 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pancreas Adenocarcinoma
Sponsor
Queen's University, Belfast
Enrollment
8
Locations
1
Primary Endpoint
Feasibility - recruitment: number of participants that agree to participate or are excluded
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this study is to establish the feasibility of delivering a prescribed, individualised supervised aerobic and resistance exercise programme during adjuvant therapy, to improve survival and reduce symptom burden in pancreatic cancer

Detailed Description

Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of the pancreas, representing 90% of all pancreatic neoplasms. The late presentation of symptoms and a lack of effective screening methods, means a large proportion (80-90%) are diagnosed with unresectable advanced disease, contributing to an unfavorable prognosis and dismal 5-year survival rate of \~5%. Intensive cancer treatments (i.e. surgery and chemotherapy) have debilitating complications including fatigue, pain and impaired physical function. Therefore, the maintenance of physical function and quality of life are seen as primary treatment goals for pancreatic patients, particularly during adjuvant therapy. Exercise training is emerging as an accepted component of patient care and evidence suggests regular exercise may induce an array of physiological and psychosocial benefits. However, there is a lack of evidence on the feasibility of delivering supervised exercise interventions to individuals with resectable PDAC undergoing adjuvant therapy. This study aims to explore the initial feasibility of delivering a supervised, individualized, and progressive concurrent exercise intervention to individuals with resectable PDAC who are undergoing adjuvant therapy, and provide data required to design a future randomized controlled trials.

Registry
clinicaltrials.gov
Start Date
August 1, 2020
End Date
August 1, 2022
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Gillian Prue

Senior lecturer in chronic illness

Queen's University, Belfast

Eligibility Criteria

Inclusion Criteria

  • age ≥ 18 years
  • histologically proven pancreatic ductal adenocarcinoma
  • complete macroscopic resection (R0 or R1 resection)
  • patients recovering from surgery in time for chemotherapy to be delivered with adjuvant intent
  • prior malignancy active within the previous 3 years other than locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • deemed medically fit by treating team to participate in exercise programme
  • able to provide informed consent.

Exclusion Criteria

  • Macroscopically remaining tumour (R2 resection or tumour node metastasis (TNM) stage IV disease)
  • Pre-existing cardiac conditions; Congestive heart failure or recent serious cardiovascular event
  • Chest pain while undertaking physical activity
  • Any related co-morbidities (diabetes; unstable angina; degenerative neuromuscular disease; mental health disorders; substance abuse)

Outcomes

Primary Outcomes

Feasibility - recruitment: number of participants that agree to participate or are excluded

Time Frame: At baseline

The number of participants that agree to participate or are excluded

Feasibility - attrition: number of participants that withdraw from the study

Time Frame: At conclusion of the 16 week exercise intervention

The number of participants that withdraw from the study

Feasibility - adherence to the exercise intervention: percentage of participants adhering to the exercise intervention

Time Frame: At conclusion of the 16 week exercise intervention

Determine the percentage of participants adhering to the exercise intervention

Feasibility - participant experience: semi-structured interviews

Time Frame: At conclusion of the 16 week exercise intervention

Determined by qualitative evaluation, using semi-structured interviews to assess experiences, accessibility and acceptability of the exercise intervention

Secondary Outcomes

  • Anthropometric assessment(At baseline, 16 weeks, 3 month follow-up)
  • Hip and waist circumference analysis(At baseline, 16 weeks, 3 month follow-up)
  • Functional muscle endurance assessment(At baseline, 16 weeks, 3 month follow-up)
  • Physical fitness assessment(At baseline, 16 weeks, 3 month follow-up)
  • Patient rated pain by questionnaire(At baseline, 16 weeks, 3 month follow-up)
  • Well-being by questionnaire(At baseline, 16 weeks, 3 month follow-up)
  • Health economics(At 16 weeks)
  • Perceived physical activity levels(At baseline, 16 weeks, 3 month follow-up)
  • Cancer-related fatigue by questionnaire(At baseline, 16 weeks, 3 month follow-up)
  • Health related quality of life by questionnaire(At baseline, 16 weeks, 3 month follow-up)

Study Sites (1)

Loading locations...

Similar Trials